Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 3 | 7 |
| List of Tables | 6 | 2 |
| List of Figures | 8 | 2 |
| Oncology Market in India: Introduction | 10 | 2 |
| GBI Research Report Guidance | 11 | 1 |
| Oncology Market in India: Market Characterization | 12 | 13 |
| Market Size | 12 | 1 |
| Annual Cost of Treatment | 13 | 1 |
| Treatment Usage Pattern | 14 | 1 |
| Diseased Population | 15 | 1 |
| Treated Population | 16 | 1 |
| Drivers | 17 | 1 |
| High Spending By Big Pharmaceutical Companies for Drug Trials | 17 | 1 |
| Larger Population Base | 17 | 1 |
| High Government Support and Initiatives | 18 | 1 |
| Barriers | 19 | 1 |
| Counterfeit Medical Products | 19 | 1 |
| Unfavorable Patent Law for Bigger Companies | 19 | 1 |
| Restrictive Pricing and Reimbursement Policies Causing Serious Problems in the Cancer Market Growth | 19 | 1 |
| Poor Infrastructure and Insufficient Trained Manpower | 20 | 1 |
| More than 80 Molecules to be launched Over the Next Seven Years, Leading to More Competition | 20 | 1 |
| Case Studies | 21 | 1 |
| Unfavorable Patent Law for Bigger Foreign Companies, Roche versus Cipla | 21 | 2 |
| Unfavorable Patent Law for Bigger Foreign Companies, Novartis Glivec | 23 | 2 |
| Oncology Market in India: Therapeutic Landscape | 25 | 29 |
| Introduction | 25 | 1 |
| Breast Cancer | 25 | 1 |
| Market Size | 25 | 1 |
| Average Annual Cost of Treatment | 26 | 1 |
| Treatment Usage Pattern | 27 | 1 |
| Diseased Population | 28 | 1 |
| Treated Population | 29 | 1 |
| Drivers | 29 | 1 |
| Increasing Per Capita Income | 29 | 1 |
| Late Age at First Childbirth | 29 | 1 |
| Fewer Children and Shorter Duration of Breast-Feeding | 30 | 1 |
| Restraints | 30 | 1 |
| Unawareness about Mammography | 30 | 1 |
| Unavailability of Experienced Medical Specialists | 30 | 1 |
| Colorectal Cancer | 31 | 1 |
| Market Size | 31 | 1 |
| Annual Cost of Treatment | 32 | 1 |
| Treatment Usage Pattern | 33 | 1 |
| Disease Population | 34 | 1 |
| Treated Population | 35 | 1 |
| Drivers | 35 | 1 |
| Migration from Rural to Urban Areas, Adoption of Western Nutritional Food Habits and Urbanization | 35 | 1 |
| Ageing Population | 35 | 1 |
| Restraints | 36 | 1 |
| Affordability | 36 | 1 |
| Tough Competition from Local Companies and Huge Generic Market | 36 | 1 |
| Complex Government Regulation and Limited-to-No Reimbursement of Expensive Patented Oncology Drugs | 36 | 1 |
| Prostate Cancer | 37 | 1 |
| Market Size | 37 | 1 |
| Annual Cost of Treatment | 38 | 1 |
| Drivers | 39 | 1 |
| Advancement of Innovative Targeted and Combination Therapies | 39 | 1 |
| Dietary Fats and Fiber | 39 | 1 |
| Restraints | 39 | 1 |
| Huge Generic Market | 39 | 1 |
| Treatment Usage Pattern | 39 | 1 |
| Disease Population | 40 | 1 |
| Treated Population | 41 | 1 |
| Lung Cancer | 42 | 1 |
| Market Size | 42 | 1 |
| Annual Cost of Treatment | 43 | 1 |
| Drivers | 44 | 1 |
| Increased Smoking Prevalence | 44 | 1 |
| Increasing Middle Class Population with Growing Economic Clout | 44 | 1 |
| Increasing Air Pollution | 44 | 1 |
| Restraints | 44 | 1 |
| Low Treatment Rate | 44 | 1 |
| Generic Dominated Market | 44 | 1 |
| Treatment Usage Pattern | 45 | 1 |
| Diseased Population | 46 | 1 |
| Treated Population | 47 | 1 |
| Non-Hodgkin s Lymphoma | 48 | 1 |
| Market Size | 48 | 1 |
| Annual Cost of Treatment | 49 | 1 |
| Drivers | 50 | 1 |
| Increasing HIV Population in India | 50 | 1 |
| Higher Diagnosis Rate | 50 | 1 |
| Increasing Incidence Population | 50 | 1 |
| Restraints | 50 | 1 |
| Less Affordability | 50 | 1 |
| Huge Generic Market | 50 | 1 |
| Treatment Usage Pattern | 51 | 1 |
| Diseased Population | 52 | 1 |
| Treated Population | 53 | 1 |
| Oncology in India: Regulatory Landscape | 54 | 13 |
| Major Regulatory Bodies in India | 54 | 1 |
| The Central Drugs Standard Control Organization (CDSCO) | 54 | 1 |
| State Drug Regulatory Authority (SDRA) | 55 | 1 |
| IPR Protection in India | 56 | 2 |
| Effect of Patent Laws on Pharmaceutical Production in India | 58 | 1 |
| Key Impact of Newer Patent Laws on India | 58 | 1 |
| Key Regulations for Conducting Oncology Research in India | 59 | 1 |
| Government Initiatives to Support Oncology Research in India | 60 | 1 |
| Focus Areas | 61 | 1 |
| Oncology in India: Pricing and Reimbursements | 62 | 1 |
| Pricing of Oncology Drugs in India | 62 | 3 |
| Reimbursement of Oncology Drugs in India | 65 | 1 |
| Cancer Health Insurance Policies | 65 | 1 |
| Insurance Policy for Cancer Treatment in India | 66 | 1 |
| Oncology in India: Pipeline Analysis | 67 | 21 |
| Key Area Focus for R&D in India | 67 | 1 |
| Pipeline Segmentation by Clinical Phase of Development | 67 | 1 |
| Pipeline Segmentation by Indication | 68 | 1 |
| Lung Cancer | 69 | 1 |
| Breast Cancer | 70 | 1 |
| Colorectal Cancer | 71 | 1 |
| Non-Hodgkin s Lymphoma | 72 | 1 |
| Prostate Cancer | 73 | 1 |
| Key Late Stage Pipeline Drugs | 74 | 1 |
| Lung Cancer | 74 | 1 |
| Stimuvax | 74 | 1 |
| AMG 706 (motesanib) | 74 | 1 |
| Vargatef (BIBF 1120) | 75 | 1 |
| Breast Cancer | 75 | 1 |
| Afinitor (everolimus) | 75 | 1 |
| BSI-201 | 76 | 1 |
| NeuVax | 76 | 1 |
| Colorectal Cancer | 77 | 1 |
| Aflibercept | 77 | 1 |
| Brivanib | 78 | 1 |
| OncoVAX | 79 | 1 |
| TroVAX | 80 | 1 |
| KRX-0401 (perifosine) | 80 | 1 |
| Non-Hodgkin s Lymphoma | 81 | 1 |
| BiovaxID | 81 | 1 |
| Afinitor (everolimus) | 82 | 1 |
| Reviroc | 83 | 1 |
| LY317615 (enzastaurin) | 83 | 1 |
| Prostate Cancer | 84 | 1 |
| Provenge (sipuleucel-T) | 84 | 1 |
| Denosumab | 85 | 1 |
| Aflibercept (VEGF Trap) | 86 | 1 |
| Ipilimumab | 86 | 1 |
| CB7630 (abiraterone acetate) | 87 | 1 |
| Oncology in India: Competitive Landscape | 88 | 24 |
| Key Indian Players in the Indian Oncology Market | 88 | 1 |
| Dr. Reddy s Lab | 88 | 1 |
| Company Overview | 88 | 1 |
| SWOT Analysis | 89 | 1 |
| Marketed Products and Product Pipeline | 90 | 1 |
| Merger, Acquisition and Partnership Deals | 91 | 1 |
| Piramal Healthcare | 91 | 1 |
| Company Overview | 91 | 1 |
| SWOT Analysis | 92 | 1 |
| Marketed Products and Product Pipeline | 93 | 1 |
| Merger, Acquisition and Partnership Deals | 94 | 1 |
| Biocon Limited | 95 | 1 |
| Company Overview | 95 | 1 |
| SWOT Analysis | 95 | 1 |
| Marketed Products and Product Pipeline | 96 | 1 |
| Cipla Ltd. | 97 | 1 |
| Company Overview | 97 | 1 |
| SWOT Analysis | 98 | 2 |
| Key Foreign Players in the Indian Oncology Market | 100 | 1 |
| Sanofi-Aventis | 100 | 1 |
| Company Overview | 100 | 1 |
| SWOT Analysis | 100 | 2 |
| Major Marketed Products and Pipeline Products | 102 | 2 |
| F. Hoffmann-La Roche Ltd/Genentech, Inc. | 104 | 1 |
| Company Overview | 104 | 1 |
| SWOT Analysis | 105 | 1 |
| Major Marketed Products and Pipeline Products | 106 | 1 |
| AstraZeneca | 107 | 1 |
| Overview | 107 | 1 |
| SWOT Analysis | 107 | 1 |
| Major Marketed Products and Pipeline Products | 108 | 1 |
| GlaxoSmithKline | 109 | 1 |
| Overview | 109 | 1 |
| SWOT Analysis | 109 | 2 |
| Major Marketed Products and Pipeline Products | 111 | 1 |
| Deals Landscape | 112 | 11 |
| Mergers and Acquisitions | 112 | 1 |
| Deals by Year | 112 | 1 |
| Deals by Type | 113 | 1 |
| Deal by Value | 114 | 1 |
| Top 10 M&A Deals | 115 | 1 |
| Strides to Acquire 50% Stake in Onco Therapies and Onco Laboratories from Aspen | 116 | 1 |
| Mitsui to Acquire 5% Stake in Arch Pharmalabs | 116 | 1 |
| Biocon to Acquire Minority Stake in Biocon Biopharmaceuticals | 116 | 1 |
| UB Group Sells 10.27% Stake in Aventis Pharma to Hoechst | 116 | 1 |
| Sanofi-Aventis Acquires Majority Stake in Shantha Biotechnics | 116 | 1 |
| Daiichi Sankyo Acquires Majority Stake in Ranbaxy Laboratories | 117 | 1 |
| Arch Pharmalabs Acquires 70% Stake in Benzochem Lifesciences | 117 | 1 |
| Fresenius Kabi Acquires 90.9% Stake in Dabur Pharma | 117 | 1 |
| Ranbaxy Laboratories Acquires 25.15% Stake in Zenotech Laboratories | 117 | 1 |
| Aspen Pharmacare Acquires Stake in Onco Therapies from Strides Arcolab | 118 | 1 |
| Licensing Agreements | 118 | 1 |
| Deals by Year | 118 | 1 |
| Deals by Value | 119 | 1 |
| Key Takeaway | 120 | 1 |
| Top 10 Licensing Deals | 120 | 1 |
| Takeda Pharmaceutical Enters into Collaboration Agreement with Alnylam Pharmaceuticals | 120 | 1 |
| Algeta Signs Licensing Agreement with Bayer | 120 | 1 |
| BioInvent and ThromboGenics Enter into an Agreement with Roche | 120 | 1 |
| Sanofi-Aventis Enters into a Licensing Agreement with Merrimack Pharmaceuticals | 121 | 1 |
| Genentech Enters into Licensing Agreement with CGI Pharmaceuticals | 121 | 1 |
| Pfizer Enters into Licensing Agreement with Coley Pharmaceutical | 121 | 1 |
| Novacea Enters into Licensing Agreement with Schering-Plough for Asentar | 121 | 1 |
| Merck Enters into Licensing Agreement with Lpath | 122 | 1 |
| Merck Signs an Agreement with Idera Pharmaceuticals | 122 | 1 |
| Taiho Pharmaceutical Signs Licensing Agreement with Sanofi-Aventis | 122 | 1 |
| Appendix | 123 | 4 |
| Market Definitions | 123 | 1 |
| Abbreviations | 123 | 1 |
| Research Methodology | 124 | 2 |
| Coverage | 124 | 1 |
| Secondary Research | 124 | 1 |
| Primary Research | 125 | 1 |
| Expert Panel Validation | 125 | 1 |
| Contact Us | 125 | 1 |
| Disclaimer | 125 | 1 |
| Sources | 126 | 1 |